B-Cell Based Gene Therapy for Inducing Tolerance

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

B-Cell Based Gene Therapy for Inducing Tolerance

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 6(2): 141-150.

Author(s): Indira Carey, Yan Su, Yufei Jiang, Jonathan Skupsky and David W Scott.

Affiliation: Professor of Surgery,Microbiology/Immunology, University of Maryland School of Medicine,Center for Vascular and Inflammatory Diseases, 800 West Baltimore St. [Room 319], Baltimore, MD, 21201, USA.


The ability of B cells to function as tolerogenic antigen presenting cells (APCs) in vitro and in vivo, makes them ideal targets for gene therapy strategies focused on the induction and re-establishment of tolerance. Current therapy methods employ retroviral vectors for infection of B cells or bone marrow cells and subsequent expression of the target antigen. Moreover, the efficacy of peptide-IgG fusion constructs which take advantage of the tolerogenic properties of IgG has been demonstrated. In this review, we discuss gene therapy approaches mediated by B cells and bone marrow cells for tolerance acquisition in various mouse models for autoimmune disease, hemophilia and transplantation. The results indicate that gene therapy strategies successfully reduce the incidence of disease, or delay disease onset in multiple mouse models for autoimmune disease and hemophilia. Additionally, gene therapy has proven effective in a mouse transplantation model. While these studies show great promise, the mechanisms involved in tolerance, including the role of regulatory T cells, will need to be more clearly defined before the transition to a clinical setting can occur.


tolerance, B cells, gene therapy, immunoglobulin fusions, retroviral vector, antigen presentation, autoimmunity, hemophilia, transplantation, bone marrow cells.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 6
Issue Number: 2
First Page: 141
Last Page: 150
Page Count: 10
DOI: 10.2174/187152307780598072
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science